Revance Therapeutics, Inc. (RVNC): Price and Financial Metrics
RVNC Price/Volume Stats
| Current price | $3.79 | 52-week high | $37.98 |
| Prev. close | $3.76 | 52-week low | $3.63 |
| Day low | $3.63 | Volume | 1,598,000 |
| Day high | $3.82 | Avg. volume | 1,790,517 |
| 50-day MA | $5.24 | Dividend yield | N/A |
| 200-day MA | $10.62 | Market Cap | 394.98M |
RVNC Stock Price Chart Interactive Chart >
Revance Therapeutics, Inc. (RVNC) Company Bio
Revance Therapeutics is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company was founded in 1999 and is based in Newark, California.
Latest RVNC News From Around the Web
Below are the latest news stories about REVANCE THERAPEUTICS INC that investors may wish to consider to help them evaluate RVNC as an investment opportunity.
Analysts Just Slashed Their Revance Therapeutics, Inc. (NASDAQ:RVNC) EPS NumbersOne thing we could say about the analysts on Revance Therapeutics, Inc. ( NASDAQ:RVNC ) - they aren't optimistic... |
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call TranscriptRevance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript November 8, 2023 Revance Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.63 EPS, expectations were $-1.1. Operator: Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s […] |
Q3 2023 Revance Therapeutics Inc Earnings CallQ3 2023 Revance Therapeutics Inc Earnings Call |
Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate UpdateNASHVILLE, November 08, 2023--Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update |
RVNC Price Returns
| 1-mo | -23.12% |
| 3-mo | -33.04% |
| 6-mo | -55.20% |
| 1-year | -88.01% |
| 3-year | -86.09% |
| 5-year | -71.91% |
| YTD | -56.88% |
| 2023 | -52.38% |
| 2022 | 13.11% |
| 2021 | -42.41% |
| 2020 | 74.61% |
| 2019 | -19.37% |
Continue Researching RVNC
Here are a few links from around the web to help you further your research on Revance Therapeutics Inc's stock as an investment opportunity:Revance Therapeutics Inc (RVNC) Stock Price | Nasdaq
Revance Therapeutics Inc (RVNC) Stock Quote, History and News - Yahoo Finance
Revance Therapeutics Inc (RVNC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...